|
ANI Pharmaceuticals, Inc. (ANIP) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
ANI Pharmaceuticals, Inc. (ANIP) Bundle
Gain insight into your ANI Pharmaceuticals, Inc. (ANIP) valuation analysis using our cutting-edge DCF Calculator! Preloaded with real ANIP data, this Excel template enables you to adjust forecasts and assumptions to accurately calculate the intrinsic value of ANI Pharmaceuticals, Inc. (ANIP).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 208.5 | 216.1 | 316.4 | 486.8 | 614.4 | 814.2 | 1,079.1 | 1,430.2 | 1,895.5 | 2,512.1 |
| Revenue Growth, % | 0 | 3.67 | 46.38 | 53.87 | 26.2 | 32.53 | 32.53 | 32.53 | 32.53 | 32.53 |
| EBITDA | 29.1 | -1.7 | 48.1 | 106.6 | 63.1 | 98.6 | 130.6 | 173.1 | 229.5 | 304.1 |
| EBITDA, % | 13.94 | -0.77914 | 15.19 | 21.9 | 10.27 | 12.11 | 12.11 | 12.11 | 12.11 | 12.11 |
| Depreciation | 44.6 | 47.3 | 57.0 | 59.8 | 67.7 | 137.7 | 182.6 | 242.0 | 320.7 | 425.0 |
| Depreciation, % | 21.41 | 21.86 | 18.01 | 12.28 | 11.02 | 16.92 | 16.92 | 16.92 | 16.92 | 16.92 |
| EBIT | -15.6 | -48.9 | -8.9 | 46.8 | -4.6 | -39.2 | -51.9 | -68.8 | -91.2 | -120.9 |
| EBIT, % | -7.47 | -22.64 | -2.81 | 9.62 | -0.75035 | -4.81 | -4.81 | -4.81 | -4.81 | -4.81 |
| Total Cash | 7.9 | 100.3 | 48.2 | 221.1 | 151.2 | 220.6 | 292.3 | 387.4 | 513.5 | 680.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 95.8 | 128.5 | 165.4 | 162.1 | 221.7 | 369.8 | 490.1 | 649.6 | 860.9 | 1,140.9 |
| Account Receivables, % | 45.95 | 59.47 | 52.29 | 33.29 | 36.09 | 45.42 | 45.42 | 45.42 | 45.42 | 45.42 |
| Inventories | 60.8 | 81.7 | 105.4 | 111.2 | 136.8 | 236.7 | 313.7 | 415.8 | 551.1 | 730.4 |
| Inventories, % | 29.17 | 37.8 | 33.3 | 22.84 | 22.26 | 29.07 | 29.07 | 29.07 | 29.07 | 29.07 |
| Accounts Payable | 11.3 | 23.0 | 29.3 | 36.7 | 45.7 | 65.6 | 86.9 | 115.2 | 152.6 | 202.3 |
| Accounts Payable, % | 5.4 | 10.63 | 9.26 | 7.54 | 7.43 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 |
| Capital Expenditure | -68.3 | -23.6 | -16.5 | -18.5 | .0 | -85.8 | -113.8 | -150.8 | -199.8 | -264.8 |
| Capital Expenditure, % | -32.77 | -10.94 | -5.2 | -3.8 | 0 | -10.54 | -10.54 | -10.54 | -10.54 | -10.54 |
| Tax Rate, % | 16.61 | 16.61 | 16.61 | 16.61 | 16.61 | 16.61 | 16.61 | 16.61 | 16.61 | 16.61 |
| EBITAT | -13.5 | -37.2 | -6.8 | 44.2 | -3.8 | -32.7 | -43.3 | -57.4 | -76.1 | -100.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -182.5 | -55.5 | -20.5 | 90.4 | -12.4 | -208.9 | -150.5 | -199.5 | -264.4 | -350.4 |
| WACC, % | 6.16 | 6.05 | 6.05 | 6.25 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -966.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -357 | |||||||||
| Terminal Value | -8,661 | |||||||||
| Present Terminal Value | -6,434 | |||||||||
| Enterprise Value | -7,400 | |||||||||
| Net Debt | 170 | |||||||||
| Equity Value | -7,570 | |||||||||
| Diluted Shares Outstanding, MM | 19 | |||||||||
| Equity Value Per Share | -391.86 |
What You Will Get
- Real ANI Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for ANI Pharmaceuticals, Inc. (ANIP).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on ANI’s fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to ANI Pharmaceuticals, Inc. (ANIP).
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility in your evaluations.
Key Features
- Comprehensive ANIP Data: Pre-loaded with ANI Pharmaceuticals' historical financial performance and future projections.
- Customizable Financial Inputs: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditure assumptions.
- Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value in response to your adjustments.
- Flexible Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive User Interface: Designed for ease of use, catering to both seasoned professionals and newcomers.
How It Works
- Download: Get the pre-formatted Excel file containing ANI Pharmaceuticals, Inc.'s (ANIP) financial data.
- Customize: Modify projections, including sales growth, EBITDA margin, and discount rate.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and analyze results immediately.
- Make Decisions: Leverage the valuation findings to inform your investment approach.
Why Choose This Calculator for ANI Pharmaceuticals, Inc. (ANIP)?
- Accurate Data: Utilize real ANI Pharmaceuticals financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the beginning.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: An intuitive design and guided instructions ensure ease of use for everyone.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessment of ANI Pharmaceuticals, Inc. (ANIP).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Offer clients precise valuation insights specific to ANI Pharmaceuticals, Inc. (ANIP).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Pharmaceutical Industry Enthusiasts: Gain insights into how pharmaceutical companies like ANI Pharmaceuticals, Inc. (ANIP) are valued in the marketplace.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for ANI Pharmaceuticals, Inc. (ANIP).
- Real-World Data: ANI Pharmaceuticals' historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to ANI Pharmaceuticals, Inc. (ANIP).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results related to ANI Pharmaceuticals, Inc. (ANIP).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.